10-Q quarterly report · filed Nov 12, 2026

ANAPTYSBIO, INC (ANAB) Q3 2026 10-Q Quarterly Report

Short answer

ANAPTYSBIO, INC (ANAB) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $30M (down 60.3% year over year) with net income of $4M.

Q3 2026 key financials · XBRL

Revenue
$30M
−60.3% YoY
Net income
$4M
−74.4% YoY
Operating margin
65.7%
EPS (diluted)
$0.11
−76.1% YoY

Source: XBRL data from the ANAPTYSBIO, INC (ANAB) Q3 2026 10-Q on SEC EDGAR. USD.

ANAPTYSBIO, INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $30.3M, down $46.0M YoY from $76.3M, primarily reflecting no milestone revenue versus $50.0M
  • Best performer, Jemperli royalties $29.6M, up $4.7M from $24.9M; worst, GSK milestone revenue $0 vs $50.0M
  • Continuing operations net income $3.9M; non-cash royalty interest expense $18.7M vs $22.5M YoY
  • Cash, cash equivalents and investments $153.0M, down from $164.1M at June 30; operating cash flow $(9.5)M vs $4.8M
  • Capital deployment: $5.9M royalty-liability repayments and $4.4M stock issuance proceeds; funding expected for at least twelve months

Risk Factors

  • Newly added operational risk: April 2026 Spin-Off split management attention between two public companies
  • Most material legal risk: Tesaro litigation trial held July 14-17, 2026, with potential loss of dostarlimab rights
  • Regulatory risk: U.S. tariffs on pharmaceutical ingredients, including China-sourced inputs, may increase Jemperli costs
  • Near-term market risk: Keytruda competition and future biosimilars could reduce Jemperli royalties
  • Financial risk: Federal NOL utilization limited to $6.4 million annually under Section 382

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ANAPTYSBIO, INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.